The recent global demand surge for Ozempic, driven largely by its off-label use for weight loss, has led to significant supply challenges in South Africa, particularly for those looking to buy Ozempic at Dischem. Originally intended for managing type 2 diabetes, Ozempic’s newfound popularity as a weight loss aid has caused widespread shortages. South Africa is no exception, with demand far exceeding supply and impacting availability at Dischem stores.
Dischem, one of South Africa's leading pharmacy chains, has faced considerable challenges in maintaining a consistent supply of Ozempic. The pharmacy chain is experiencing frequent stockouts, especially for the lower dosages commonly prescribed for diabetes management. This issue is compounded by the fact that Ozempic’s manufacturer, Novo Nordisk, has struggled globally to keep up with demand despite significant investments in expanding production capacity.
To address these shortages, Dischem has implemented several strategies. They are prioritizing the allocation of available stock to diabetic patients who rely on Ozempic for blood sugar management. This approach aims to mitigate the impact of the drug’s off-label use on those who need it most. Additionally, Dischem is working closely with Novo Nordisk to improve supply forecasting and ensure more reliable deliveries. The pharmacy chain has also enhanced its communication with customers, providing updates on stock availability and advising on potential alternatives where necessary.
However, the situation remains fluid, with ongoing global supply constraints likely to continue affecting availability in South Africa. Dischem’s efforts are part of a broader strategy to manage this high-demand period while ensuring that critical needs are met as effectively as possible.